lichen planopilaris. lichen planopilaris
Conditions
Interventions
Intervention 1: Clobetasol 0.05%(a potent topical steroid) lotion 30 drops daily,at least 6 months,Behvarzan company. Intervention 2: Cap cellcept(an immunosuppressive agent as we know it by mycopheno
Treatment - Drugs
Clobetasol 0.05%(a potent topical steroid) lotion 30 drops daily,at least 6 months,Behvarzan company.
Cap cellcept(an immunosuppressive agent as we know it by mycophenolate mofetil) 2gr daily,it has 500mgr capsules which given as 1gr BD or 2gr DAILY for at least 6months,Razi company
Sponsors
Vice chancellor for research of Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
15 Years to 70 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: patients with histologically approved diagnosis of scalp lichen planopilaris who consent to participate in the study ; no history of any kind of treatment for the lichen planopilaris for at least one month before entering the study ; no history of hepatic, renal, cardiac, pulmonary, hematologic, neurologic and malignancies or peptic ulcer diseases. ; no pregnancy or lactation or intention to pregnancy for at least one year following the onset of treatment ; no history of allergies to any of the components of medications ; no erosive mucosal disease, or generalized cutaneous disease. Exclusion criteria: ; occurrence of treatment complications that are inconsistent with continuation of therapy ( e.g. not resolving by dosage reduction ) or not tolerable by the patient. ; no desire to continue the study by the patients for any reason including no satisfaction of the treatment results ; patients unresponsive to treatment after 3 months of receiving the medication.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response to treatment. Timepoint: 0,2,4,6 Months after the initiation of study. Method of measurement: LPPAI(lichenplanus activity index). | — |
Secondary
| Measure | Time frame |
|---|---|
| CBC,DIFF. Timepoint: For Clobetasol lotion at the beginning of study and for Cellcept 0,2,4,6 months after the initiation of study. Method of measurement: Laboratory assessment.;Satisfaction of treatment(qualitative). Timepoint: After 2,4,6 months of the initiation of study. Method of measurement: Qualitative(excellent,good,medium,low,no effectiveness)by questionnaire.;Liver function. Timepoint: For Clobetasol lotion at the beginning of study and for Cellcept 0,2,4,6 months after the initiation of study. Method of measurement: Laboratory assessment(AST,ALT).;Renal function. Timepoint: For Clobetasol lotion at the beginning of study and for Cellcept 0,2,4,6 months after the initiation of study. Method of measurement: Laboratory assessment(BUN,Cr).;ESR. Timepoint: For Clobetasol lotion at the beginning of study and for Cellcept 0,2,4,6 months after the initiation of study. Method of measurement: Laboratory assessment. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAzadeh Goodarzi
Tehran University of Medical Sciences
Outcome results
None listed